A B S T R A C T
Cross-sectional studies represent the second line of evidence (after case reports) in the ladder of evidence aimed at defining disease aetiology. This study design is used to generate hypotheses about the determinants of a given disease but also to investigate the accuracy of diagnostic tests and to assess the burden of a given disease in a population. The intrinsic limitation of cross-sectional studies, when applied to generate aetiological hypotheses, is that both the exposure under investigation and the disease of interest are measured at the same point in time. For this reason, generally the crosssectional design does not provide definitive proofs about cause-and-effect relationships. An advantage of crosssectional studies in aetiological and diagnostic research is that they allow researchers to consider many different putative risk factors/diagnostic markers at the same time. For example, in a hypothetical study aimed at generating hypotheses about the risk factors for left ventricular hypertrophy (LVH) in patients with chronic kidney disease, investigators could look at several risk factors as potential determinants of LVH (age, gender, cholesterol, blood pressure, inflammation, etc.) with minimal or no additional costs. In this article, we make examples derived from the nephrology literature to show the usefulness of cross-sectional studies in clinical and epidemiological research.
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I N T R O D U C T I O N
Patients with chronic kidney disease (CKD) and end-stage kidney failure are at high risk of cardiovascular (CV) morbidity and mortality [1, 2] and large-scale randomized clinical trials (RCTs) performed so far [3] failed to demonstrate a meaningful clinical benefit of various treatments being investigated in these patients. Furthermore, traditional and non-traditional risk factors only in part explain the high CV risk in patients with kidney diseases [4] , and for this reason the identification of new and unsuspected CV risk factors represents a tantalizing research priority in nephrology. While RCTs are the gold standard study design for testing the intended effect of therapy on a given pathophysiological pathway to assess causality [5] , the process for the identification of risk factors generally starts by anecdotal observations, studies in experimental models and case reports [6] followed by cross-sectional studies, the latter representing the second line of evidence for discovery and explanation [6] . In other words, cross-sectional studies are useful in the laborious initial phases of research when investigators generate and frame novel scientific hypotheses [6, 7] . Furthermore, this study design is very important to test the accuracy of diagnostic tests [8] and to assess the burden of a given disease in a population [7] .
In this article, we report some examples illustrating the application of cross-sectional studies in renal diseases for (i) generating aetiological hypotheses, (ii) assessing the value of diagnostic tests and (iii) estimating the burden of a given disease (e.g. CKD) in the population. 
The inherent limitation of cross-sectional studies when applied to test aetiological hypotheses is that both the exposure (i.e. the putative risk factor) and the disease (i.e. the outcome variable) are measured at the same point in time. For this reason, generally the cross-sectional design cannot establish which is the cause and which is the effect [7, 9] , apart from some situations such as genetic associations studies where the causal role of the gene in question is firmly established. These studies are also prone to selection bias (or survival bias) [10] and confounding [7, 9] , the latter occurring when an observed association between a candidate risk factor and a given disease does not reflect a causal relationship but instead is due to an extraneous factor which (i) correlates with the outcome of interest, (ii) correlates with the risk factor being investigated and (iii) is not in the causal pathway between exposure and outcome ( Figure 1 ) [9] . Here we discuss the importance of cross-sectional studies in aetiological research in nephrology by describing a study by Grassi et al. [11] . Sympathetic activity [12] and circulating levels of the endogenous inhibitor of the nitric oxide system asymmetric dimethyl-arginine (ADMA) [13] are substantially raised in CKD patients and associate with a high CV risk in this population. Sympathetic stimulation in healthy individuals impairs endothelial-dependent vasodilation [14] and ADMA triggers sympathoexcitatory effects [15] in animal models, suggesting that the two risk factors may influence each other. Grassi et al.
[11] made a preliminary exploration of this hypothesis by investigating the cross-sectional relationship between efferent postganglionic muscle sympathetic nerve traffic (MSNA, as measured by microneurography) and circulating levels of ADMA in a series of 48 stage 2-4 CKD patients. In brief, they tested the interrelationships between MSNA, ADMA and estimated glomerular filtration rate (eGFR). In unadjusted analyses and in analyses adjusted for potential confounders, they found an independent, direct inter-relationship between ADMA levels and MSNA, which was in keeping with the previous biological knowledge. However, this study-like all cross-sectional studies-generally could not resolve the problem of identifying which comes first, the 'egg' (purportedly sympathetic activity) or the 'hen' (ADMA). The issue could be solved only into a subsequent longitudinal study where the evolution of ADMA levels after renal denervation (an intervention reducing sympathetic activity) was measured before and after denervation and compared with that of suitable control groups where no such an intervention was applied [16] . This longitudinal study suggested that in patients with resistant hypertension, changes in sympathetic activity after renal denervation associate with simultaneous changes in the plasma levels of ADMA. These observations are compatible with the hypothesis (generated in the previous cross-sectional study [11] ) that sympathetic nervous system may exert a primary role in modulating circulating levels of ADMA in resistant hypertension patients.
CROSS-SECTIONAL STUDIES IN DIAGNOSTIC RESEARCH
Diagnosis, together with prognosis, therapy and prevention, is one of the four fundamental components of clinical medicine [17] . Diagnostic tests measure the agreement between a given marker of disease and a specific gold standard test. When the test gives a result expressed in binary terms (presence/absence of the disease), as indices of diagnostic accuracy investigators use sensitivity (the proportion of patients with positive test among those affected by the disease), specificity (the proportion of patients with negative test among those unaffected by the disease), positive predictive value (the proportion of patients with the disease among those with positive test) and negative predictive value (the proportion of patients without the disease among those with negative test). Sensitivity and specificity are fixed characteristics of a given diagnostic test, whereas positive and negative predictive values are critically dependent on the prevalence of the disease [18] . According to the test result, an investigator can also compare the likelihood that patient truly had the disease of interest with the corresponding probability that he/she was healthy. The ratio of these probabilities is the positive likelihood ratio (þLR), which is calculated as sensitivity (true positive rate) divided by '1 À specificity' (false positive rate). For example, a þLR of 5 for a given test implies that of every six patients given as affected by the disease on the basis of the test, five are true positives and one is a false positive. Negative likelihood ratio (ÀLR) is calculated as '1 À sensitivity' (false negative) divided by specificity (true negative). For example, a ÀLR of 0.2 would indicate a 5-fold decrease (1/0.2 ¼ 5) in the odds of having the disease of interest in a patient with a negative result of the test. If the test results are not expressed in binary terms but as a continuous variable and/or the investigator does not know the test cut-off for defining an individual as affected or unaffected by the disease of interest, the accuracy of a quantitative test across the whole range of its values is assessed by receiver operating characteristic (ROC) curve analysis [19] . A ROC curve is a graph plotting the true positive rate (sensitivity) as a function of the false positive rate (1 À specificity) across a series of cut-off values across the whole range of values of the diagnostic test (Figure 2) . The bigger the area under the ROC curve, the higher the diagnostic accuracy of the test. An ROC curve area of 1 implies perfect discrimination (100% accuracy), whereas an ROC curve of 0.50 indicates complete absence of diagnostic accuracy. By using the ROC curve,
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Confounder FIGURE 1: Schematic representation of a confounder. In an exposure-outcome pathway, a confounder is a variable that is associated with the exposure, is not an effect of the exposure, does not lie in the causal pathway between the exposure and the outcome, and represents a risk factor for the outcome. an investigator can derive the optimal cut-off of the biomarker being investigated, and such a choice depends on the statistical and clinical reasons. From a pure statistical point of view, if false negative and false positive results are considered equivalent, by using the coordinates of the ROC curve we can identify the best cut-off, i.e. the value of the candidate diagnostic biomarker that maximizes the difference between true positive and false positive rates. Vice versa, a clinician could be interested to adopt a cut-off of the biomarker, always derived by the ROC curve, in order to maximize sensitivity or specificity rather than both. In this last case, the cut-off value fully depends on clinical considerations. In a cross-sectional study, Mallamaci et al. [20] investigated the diagnostic accuracy of Troponin T (cTNT) for identifying left ventricular hypertrophy (LVH) in dialysis patients without congestive heart failure at enrollment. Serum cTNT had an area under the ROC curve of 72% (P < 0.001) for discriminating patients with from those without LVH. The authors also identified the best c-TNT cut-off, i.e. the value of this biomarker (55 ng/L) that maximizes the difference between true and false positive rates. They found that cTNT had a similar degree of sensitivity and specificity for the detection of LVH (70% and 68%, respectively). The positive predictive value was relatively high (87%), a value that should be interpreted with caution because of the high prevalence of LVH in the dialysis population (about 70%). The negative predictive value of cTNT was rather low (only 44%) and again such a figure could depend on the high frequency of LVH in the dialysis population. By using sensitivity and specificity, the authors calculated the þLR and they found a value of 2, which implies that of every three patients given as affected by LVH by high cTNT (>55 ng/L), two patients are true positives and one patient is false positive. The ÀLR resulted to be 0.43, which indicates a 2.3-fold decrease (1/0.43 ¼ 2.3) in the odds of having LVH in a patient with a negative cTNT result or alternatively that of every (about) three patients given as unaffected by LVH by the test, two patients are true negatives and one patient is false negative.
CROSS-SECTIONAL STUDIES FOR ASSESSING DISEASE BURDEN IN THE POPULATION
Information on the burden of a given disease in the population is essential for prioritizing policies by governmental and health institutions and health care planners. For example, knowing in detail the burden of CKD in the elderly population, i.e. the population where this condition is most prevalent, is of obvious public health relevance. To this scope, Ebert et al. [21] investigated the burden of renal dysfunction (as assessed by eGFR and albuminuria levels) across age categories in a geriatric German population (aged >70 years). The study included a total of 2069 individuals with a mean age of 80 years. The authors found that the prevalence of stage 3-5 CKD ranged widely (from 38% to 62%) depending on the equation used to estimate GFR. They also found that creatinine, cystatin C and albumin/creatinine ratio increased with increasing age for both men and women.
The results of their survey may be useful for patient-centred care and for scheduling health care expenditures, from a public health perspective, in the growing field of geriatric nephrology. The relevance of these studies of the kind is highlighted in full by a recent systematic review of surveys (cross-sectional studies) on CKD prevalence in Europe on behalf of the European CKD Burden Consortium [22] .
C O N C L U S I O N S
Cross-sectional studies represent an irreplaceable instrument to address diagnostic hypotheses and to assess disease burden in nephrology. They are also useful to generate aetiological hypotheses to test in cohort studies and/or in specifically designed intervention studies. When planning a cross-sectional study, attention should be given by investigators to minimize selection bias during patient enrollment. Furthermore, the data analysis of a cross-sectional study should take into account the intrinsic limitation due to the absence of temporal dimension in this study design and be carried out by an accurate identification of potential confounders affecting the pathophysiological pathway (exposure-disease) being investigated. The interpretation of the results of a cross-sectional study should accurately consider their biological plausibility and their consistency with previous studies in experimental models.
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